Epigenetic aberrations in Cholangiocarcinoma: Potential biomarkers and promising target for novel therapeutic strategies

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue SUPPL.1, 2012, Pages 41-45

  Limpaiboon, Temduang ^a,b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Biomarkers; Cancer; Epigenetics; Histone modifications; Methylation

Indexed keywords

BIOLOGICAL MARKER;

BILE DUCT CARCINOMA; BILE DUCT TUMOR; HUMAN; INTRAHEPATIC BILE DUCT; RISK FACTOR; SCLEROSING CHOLANGITIS;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; HUMANS; RISK FACTORS;

EID: 84874104100     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.KKSuppl.41     Document Type: Review

References (55)

1. Ahrendt SA, Eisenberger CF, Yip L, et al (1999). Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res, 84, 88-93.
2. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
3. Baylin SB (2005). DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol, 2, 1-11.
4. Beisler JA (1978). Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem, 21, 204-8.
5. Berger SL (2002). Histone modifications in transcriptional regulation. Curr Opin Genet Dev, 12, 142-8.
6. Bird A (2002). DNA methylation patterns and epigenetic memory. Genes Dev, 16, 6-21.
7. Brennecke J, Stark A, Russell RB, Cohen SM (2005). Principles of microRNA-target recognition. PLoS Biol, 3, 85.
8. Calin GA, Sevignani C, Dumitru CD, et al (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA, 101, 2999-3004.
9. Carew JS, Giles FJ, Nawrocki ST (2008). Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett, 269, 7-17.
10. Cheng JC, Matsen CB, Gonzales FA, et al (2003). Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst, 95, 399-409.
11. Cheng JC, Weisenberger DJ, Gonzales FA, et al (2004). Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol, 24, 1270-8.
12. Cheung P, Lau P (2005). Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol, 19, 563-73.
13. Chinnasri P, Pairojkul C, Jearanaikoon P, et al (2009). Preferentially different mechanisms of inactivation of 9p21 gene cluster in liver fluke-related cholangiocarcinoma. Hum Pathol, 40, 817-26.
14. Chuang JC, Jones PA (2007). Epigenetics and microRNAs. Pediatr Res, 61, 24-9.
15. Esteller M (2008). Epigenetics in cancer. N Eng J Med, 358, 1148-59.
16. Grant PA (2001). A tale of histone modifications. Genome Biol, 2, 1-6.
17. Hamilton JP (2010). Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics, 2, 233-43.
18. Han L, Witmer PD, Casey E, Valle D, Sukumar S (2007). DNA methylation regulates microRNA expression. Cancer Biol Ther, 6, 1284-8.
19. Herman JG, Baylin SB (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 349, 2042-54.
20. Holliday R (1987). The inheritance of epigenetic defects. Science, 238, 163-70.
21. Huang L, Frampton G, Liang L, DeMorrow S (2010). Aberrant DNA methylation profile in cholangiocarcinoma. World J Gastrointest Pathophysiol, 1, 23-9.
22. Huertas D, Sendra R, Muñoz P (2009). Chromatin dynamics coupled to DNA repair. Epigenetics, 4, 31-42.
23. Isomoto H (2009). Epigenetic alterations associated with cholangiocarcinoma. Oncol Rep, 22, 227-32.
24. Karakatsanis A, Papaconstantinou I, Gazouli M, et al (2011). Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog, 10, 21864.
25. Karube Y, Tanaka H, Osada H, et al (2005). Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci, 96, 111-5.
26. Kelly WK, Marks PA (2005). Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol, 2, 150-7.
27. Khaenam P, Jearanaikoon P, Pairojkul C, Bhudisawasdi V, Limpaiboon T (2010). Genetic and epigenetic alterations of RIZ1 and the correlation to clinicopathological parameters in liver fluke-related cholangiocarcinoma. Exp Therapeutic Med, 1, 385-90.
28. Khaenam P, Niibori A, Okada S, et al (2012). Contribution of RIZ1 in proliferation and migration of liver fluke-related cholangiocarcinoma cell line. Asian Pac J Cancer Prev, in press.
29. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD (2005). Cholangiocarcinoma. Lancet, 366, 1303-14.
30. Khorasanizadeh S (2004). The nucleosome: from genomic organization to genomic regulation. Cell, 116, 259-72.
31. Kouzarides T (2007). Chromatin modifications and their function. Cell, 128, 693-705.
32. Lazaridis KN, Gores GJ (2005). Cholangiocarcinoma. Gastroenterology, 128, 1655-67.
33. Lewis BP, Burge CB, Bartel DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120, 15-20.
34. Li B, Carey M, Workman JL (2007). The role of chromatin during transcription. Cell, 128,707-19.
35. Lim LP, Lau NC, Garrett-Engele P, et al (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433, 769-73.
36. Limpaiboon T, Khaenam P, Chinnasri P, et al (2005). Promoter hypermethylation is a major event of hMLH1 gene inactivation in liver fluke related cholangiocarcinoma. Cancer Lett, 217, 213-9.
37. Lund AH, van Lohuizen M (2004). Epigenetics and cancer. Genes Dev, 18, 2315-35.
38. Marks PA, Richon VM, Miller T, Kelly WK (2004). Histone deacetylase inhibitors. Adv Cancer Res, 91, 137-68.
39. Marquez VE, Barchi JJ Jr, Kelley JA, et al (2005). Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides Nucleotides Nucleic Acids, 24, 305-18.
40. Reik W, Lewis A (2005). Co-evolution of X-chromosome inactivation and imprinting in mammals. Nat Rev Genet, 6, 403-10.
41. Sandhu DS, Shire AM, Roberts LR (2008). Epigenetic DNA methylation in cholangiocarcinoma: potential role in pathogenesis, diagnosis and identification of treatment targets. Liver Int, 28, 12-27.
42. Sasaki M, Yamaguchi J, Itatsu K, Ikeda H, Nakanuma Y (2008). Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol, 215, 175-83.
43. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC (2006). Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res, 66, 1277-81.
44. Shaib Y, El-Serag HB (2004). The epidemiology of cholangiocarcinoma. Semin Liver Dis, 24, 115-25.
45. Shao Y, Gao Z, Marks PA, Jiang X (2004). Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA, 101, 18030-5.
46. Sharma S, Kelly TK, Jones PA (2010). Epigenetics in cancer. Carcinogenesis, 31, 27-36.
47. Shukla V, Vaissière T, Herceg Z (2008). Histone acetylation and chromatin signature in stem cell identity and cancer. Mut Res, 637, 1-15.
48. Sriraksa R, Zeller C, El-Bahrawy MA, et al (2011). CpG-island methylation study of liver fluke-related cholangiocarcinoma. Br J Cancer, 104, 1313-8.
49. Stutes M, Tran S, DeMorrow S (2007). Genetic and epigenetic changes associated with cholangiocarcinoma: From DNA methylation to microRNAs. World J Gastroenterol, 13, 6465-9.
50. Taby R, Issa JJ (2010). Cancer epigenetics. CA Cancer J Clin, 60, 376-92.
51. Tischoff I, Wittekind C, Tannapfel A (2006). Role of epigenetic alterations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg, 13, 274-9.
52. Valeri N, Vannini I, Fanini F, et al (2009). Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome, 20, 573-80.
53. Vigushin DM, Coombes RC (2002). Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs, 13, 1-13.
54. Weber M, Hellmann I, Stadler MB, et al (2007). Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet, 39, 457-66.
55. Yoo CB, Jones PA (2006). Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov, 5, 37-50.